恒瑞医药A股回购进展公告详解
一、公告要点概览
- 回购方案初次披露日期：2025年8月21日
- 回购实施期限：2025年8月20日至2026年8月19日
- 预计回购金额：人民币10亿元至20亿元
- 回购用途：本次回购拟用于员工持股计划或股权激励，不作注册资本减少、可转债转换或维护股东权益等用途
- 累计已回购股份数量：1,205.62万股，占总股本0.18%
- 已回购金额：77,198.09万元（不含交易费用）
- 实际回购价格区间：53.52元/股至70.00元/股
二、详细内容解读与投资者关注要点
江苏恒瑞医药股份有限公司于2025年8月20日召开的董事会审议通过了A股股份回购方案。公司决定使用自有资金，通过上海证券交易所集中竞价交易方式回购部分A股股份，主要用于实施员工持股计划或股权激励。
本次回购方案设定了最高回购价格为90.85元/股，总回购金额下限为10亿元，上限为20亿元，回购期限为董事会通过后12个月内。截止至2026年5月31日，公司已回购股份1,205.62万股，占总股本0.18%。此次已支付的回购总金额为77,198.09万元，实际回购价格区间为53.52元/股至70.00元/股，未超过此前设定的价格上限。
需要特别强调的是，2026年5月公司未进行新的回购操作，累计回购股份数、回购金额及价格区间均与前月持平，显示公司在回购操作上较为谨慎，可能与市场环境或内部资金安排相关。
- 本次回购仅用于员工持股计划或股权激励，不会减少注册资本，也不涉及可转债转换或公司价值维护相关操作。
- 回购进度的透明披露，符合监管要求，并提醒投资者密切关注后续进展。
三、对股东可能产生的重要影响
- 回购力度：回购金额上限高达20亿元，标志公司对未来发展及员工激励的信心，有助于提升市场信心。
- 回购价格带：实际回购区间远低于最高价，有望对公司股价形成底部支撑，可能带来市场正面预期。
- 股份回购占比：目前回购股份占比0.18%，未来若继续推进，将对流通股本构成影响，间接促进股东权益提升。
- 回购暂停风险：5月无新增回购，投资者需关注公司后续回购节奏及资金安排，若回购进度放缓或调整，可能对市场预期有一定影响。
四、投资者须知及风险提示
- 公司将根据市场情况择机实施回购，并严格遵守相关法规和信息披露义务。
- 投资者需注意，回购进度可能因市场环境、公司资金状况等因素变化而调整。
五、结语
恒瑞医药的A股回购计划代表公司对未来发展的信心和对员工激励的重视。虽然5月未有新增回购，但整体回购进度和资金投入对市场情绪和股价均可能形成支撑。投资者应密切关注后续回购进展及相关公告，合理评估投资风险。
免责声明：本文信息基于公司公告整理，仅供投资者参考，不构成任何投资建议。股市有风险，投资需谨慎。
English Version
Hengrui Pharma Progress Update on A-share Buyback Plan: Detailed Analysis
1. Key Highlights
- Initial Disclosure Date of Buyback Plan: August 21, 2025
- Buyback Period: August 20, 2025 to August 19, 2026
- Expected Buyback Amount: RMB 1 billion to RMB 2 billion
- Buyback Purpose: For employee stock ownership plan or equity incentives only
- Total Shares Repurchased: 12.0562 million shares, accounting for 0.18% of total share capital
- Total Amount Paid: RMB 771.9809 million (excluding transaction fees)
- Actual Buyback Price Range: RMB 53.52/share to RMB 70.00/share
2. In-depth Details and Investor Focus
Jiangsu Hengrui Medicines Co., Ltd. approved an A-share buyback plan on August 20, 2025. The company will use its own funds, via centralized bidding on the Shanghai Stock Exchange, to repurchase A-shares for the sole purpose of implementing employee stock ownership or equity incentive plans.
The maximum repurchase price is set at RMB 90.85/share, with the total amount capped at RMB 2 billion and a minimum of RMB 1 billion. The buyback period is twelve months from the date of board approval. As of May 31, 2026, the company had repurchased 12.0562 million shares, representing 0.18% of the total share capital, with a total payment of RMB 771.9809 million. The actual buyback price ranged from RMB 53.52 to RMB 70.00 per share, well below the set price ceiling.
It is noteworthy that there were no new repurchases in May 2026, indicating a cautious approach in execution, possibly due to market conditions or internal considerations.
- The buyback is strictly for employee stock plans or incentives, and will not reduce registered capital or serve for convertible bond conversion or value maintenance.
- Progress is disclosed in accordance with regulations, and investors are reminded to closely follow subsequent announcements.
3. Key Issues for Shareholders and Potential Price Sensitivity
- Buyback Scale: The plan’s upper limit of RMB 2 billion demonstrates management’s confidence and commitment to employee incentives, which may positively impact market sentiment.
- Buyback Price Range: The lower actual price range could provide a price floor and support share value.
- Proportion Repurchased: With 0.18% of shares repurchased, continued execution may further reduce floating shares and enhance shareholder returns.
- Buyback Pausing Risk: No repurchases in May calls for attention to the company’s future pace and funding, as any change may affect market expectations.
4. Investor Reminders and Risk Disclosure
- The company will continue to repurchase shares as appropriate, in strict compliance with relevant laws and timely information disclosure.
- Investors should note that repurchase progress is subject to change based on market conditions and internal capital allocation.
5. Conclusion
Hengrui Pharma’s A-share buyback shows confidence in its development and its dedication to employee incentives. Although there was no new buyback in May, the plan’s scale and progress may support market sentiment and the share price. Investors should stay alert to future updates and assess risks accordingly.
Disclaimer: This article is for reference only, based on company announcements. It does not constitute investment advice. The stock market involves risks. Please invest cautiously.
